| Description | Droxicainide is an antiarrhythmic agent. |
| In vivo | In coronary artery occlusion studies, Droxicainide reduced the progression of hypoperfusion to necrosis and reduced the infarct size in dogs[1].Droxicainide reduces ansa node, atrioventricular excitability and contractility, and increases intractable studies on spontaneous beating atrium, electrical stimulation atrium and isolated papillary muscles in rats[2]. |
| molecular weight | 276.37 |
| Molecular formula | C16H24N2O2 |
| CAS | 78289-26-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 50 mg/mL (180.92 mM) |
| References | 1. Faria DB, et al. Effects of lidocaine and droxicainide on myocardial necrosis: a comparative study. J Am Coll Cardiol. 1983 Jun;1(6):1447-52. 2. Helgesen KG, et al. Comparison of electrophysiological and mechanical effects of droxicainide and lidocaine on heart muscle isolated from rats. Acta Pharmacol Toxicol (Copenh). 1984 Oct;55(4):303-7. |